<SEC-DOCUMENT>0001193125-19-037998.txt : 20190213
<SEC-HEADER>0001193125-19-037998.hdr.sgml : 20190213
<ACCEPTANCE-DATETIME>20190213161702
ACCESSION NUMBER:		0001193125-19-037998
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190213
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190213
DATE AS OF CHANGE:		20190213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		19597366

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d670443d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): February&nbsp;13, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-14888</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0969592</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting, PA 19462 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(267) <FONT STYLE="white-space:nowrap">440-4200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Results of Operations and Financial Condition. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The disclosure contained under the heading <FONT STYLE="white-space:nowrap">&#147;Year-End</FONT> Cash, Cash Equivalents and Short-Term Investments&#148; in
Item 8.01 below is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U><FONT STYLE="white-space:nowrap">Year-End</FONT> Cash, Cash Equivalents and Short-Term Investments </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, Inovio Pharmaceuticals, Inc. (the &#147;<B><I>Company</I></B>&#148;) had approximately $81.2&nbsp;million of cash, cash
equivalents and short-term investments. This amount is unaudited and preliminary, is subject to completion of financial closing procedures that could result in changes to the amount, and does not present all information necessary for an
understanding of the Company&#146;s financial condition as of December&nbsp;31, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Convertible Senior Notes </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2019, the Company issued a press release announcing its proposed plans to offer, subject to market and other conditions, up to
approximately $65 million aggregate principal amount of convertible senior notes due 2024 (the &#147;notes&#148;) in a private offering to qualified institutional buyers pursuant to Rule&nbsp;144A of the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;). The Company also expects to grant the initial purchasers for the offering a <FONT STYLE="white-space:nowrap">13-day</FONT> option to purchase up to an additional $20&nbsp;million aggregate principal amount of notes. A
copy of the press release is attached hereto as Exhibit&nbsp;99.1 and incorporated by reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Form
<FONT STYLE="white-space:nowrap">8-K</FONT> does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any state in which such offer,
solicitation or sale would be unlawful. Any offers of the securities would be made only by means of a confidential offering memorandum. The offer and sale of these securities have not been registered under the Securities Act, or any state securities
laws and, unless so registered, these securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Special Note Regarding Forward-Looking Statements </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> contains &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended.
These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause the Company&#146;s actual results, performance or achievements to be materially different from any future results,
performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#147;may&#148;, &#147;will&#148;, &#147;should&#148;, &#147;could&#148;,
&#147;would&#148;, &#147;expects&#148;, &#147;plans&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;estimates&#148;, &#147;projects&#148;, &#147;predicts&#148;, &#147;potential&#148; and similar expressions intended to identify
forward-looking statements. These statements reflect the Company&#146;s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance
on these forward-looking statements. Also, these forward-looking statements represent the Company&#146;s estimates and assumptions only as of the date of this Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d670443dex991.htm">Press Release dated February&nbsp;13, 2019 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>INOVIO PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: February&nbsp;13, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Peter Kies</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;Peter Kies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;Chief Financial Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d670443dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g670443g62b91.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals Announces </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Proposed Convertible Senior Notes Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, Pa., February&nbsp;13, 2019 &#151; Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today its intention to offer, subject to market and
other conditions, $65&nbsp;million aggregate principal amount of convertible senior notes due 2024 (the &#147;notes&#148;) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended
(the &#147;Securities Act&#148;). Inovio also expects to grant the initial purchasers of the notes a <FONT STYLE="white-space:nowrap">13-day</FONT> option to purchase up to an additional $20&nbsp;million aggregate principal amount of notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes will be senior unsecured Inovio obligations and will accrue interest payable semiannually in arrears. The notes will be convertible in certain
circumstances into cash, shares of Inovio&#146;s common stock, or a combination of cash and shares of Inovio&#146;s common stock, at Inovio&#146;s election. The interest rate, initial conversion rate and other terms of the notes will be determined
at the time of the pricing of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio anticipates using the net proceeds from this offering for general corporate purposes, including
clinical trial expenses, research and development expenses, general and administrative expenses and manufacturing expenses, and for other business development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offer and sale of the notes and the shares, if any, issuable upon conversion of the notes have not been and will not be registered under the Securities
Act or applicable state securities laws, and the notes and such shares may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state
securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes or any shares issuable upon conversion of the notes, nor shall there be any sale of the notes or such shares, in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA immunotherapies that transform the treatment
of cancer and infectious diseases. Inovio&#146;s proprietary platform technology applies next-generation antigen sequencing and DNA delivery to activate potent immune responses to targeted diseases. The technology functions exclusively in vivo, and
has been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. Inovio has reported generating T cells whose killing capacity correlates with relevant clinical
outcomes. Inovio&#146;s most advanced clinical program, <FONT STYLE="white-space:nowrap">VGX-3100,</FONT> is in Phase 3 for the treatment of <FONT STYLE="white-space:nowrap">HPV-related</FONT> cervical
<FONT STYLE="white-space:nowrap">pre-cancer.</FONT> Also in development are Phase 2 immuno-oncology programs targeting head and neck cancer, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola,
MERS, and HIV. Partners and collaborators include MedImmune, Regeneron, Roche/Genentech, ApolloBio Corporation, The Wistar Institute, The Bill&nbsp;&amp; Melinda Gates Foundation, the University of Pennsylvania, Parker Institute for Cancer
Immunotherapy, CEPI, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements that involve a number of risks and uncertainties such as those, among others, relating to
Inovio&#146;s expectations regarding the completion, timing and size of its proposed offering. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties
associated with market conditions, whether Inovio will offer the notes or be able to consummate the proposed offering at the anticipated size or on the anticipated terms, or at all, the satisfaction of closing conditions related to the proposed
offering, as well as risks and uncertainties associated with Inovio&#146;s business and finances in general, and the other risks described in Inovio&#146;s quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended
September&nbsp;30, 2018. Inovio undertakes no obligation to update the statements contained in this press release after the date hereof. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g670443g62b91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g670443g62b91.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !1 20# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[<_X+"_\
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M6I^$%\-V"3A+K5[V]@:T@CS@NOENS2\<@("3WQU%*PG<_>GX8?$33?B[\-]
M\5:-(TND^)-/@U.S=AAC%-&LB9'8X89'8UNUS7P9^%]C\$?A'X8\':8TDFG^
M%]+MM*MWD^_(D,2QAF]SMR?<UTM2,**** "BBB@ HHHH **** "BOB/_ (*_
M_P#!3;QA_P $\=0\!1>%=#\-:POBN.^>Y.JQSN8C ;<+L\N1.OG-G.>@K,_X
M)%_\%4?&G_!0;X@^+=(\4:#X7TB#P_IT5Y"^E13H\C-)L(;S)7&,>F* N?=]
M%%?,W_!5C]M?Q%^P9^S?I_C/PSI>BZM?W>NP:4\.II*T*QO!<2%@(W0[LQ*.
MN,$\4 ?3-%?F1_P3I_X+@^./VM?VFK'PAXNT'P+H'AY["]O[R_M5N(6M4M[=
MYBY>2=D51L^8D<#/(KDOVW_^#BJZTOQ/>^'_ ()Z7836=HYB;Q)JL+2?:2."
MUO!P%7T:3)/]Q:=A7/UDHK^>&X_X+8?M-3ZH;K_A9MTA+;O+72; 1CVV^1C%
M?1W[(O\ P<:^+]"\3VFF_&#2+#7]#G=8Y=7TNW%M?6@/61HE/E2@?W55#UY/
M0EF%S]D**RO _C?2?B5X/TW7]!O[?5=&UBW2[LKNW;='<1.,JP/T['D=#S6K
M2&%%%% !17,_%KXR>%O@/X)N?$?C#7=.\/:+:<275Y+L4L>B*/O.YP<*H+'L
M#7RIXK_X*/?%CXRLT7P$^ _B3Q%8.=L/B+Q0O]E:?.,#YXDD:,R)SU\Q3_LU
MZN R;%XR//2BE!;RDU&*_P"WI-*_EOY'DYAG>$P4E3JR;F]HQ3E)_P#;L4W;
MSV\S[1HK\Y/%^F_\%%_%D;3VUWX)\/;AG[+8?V<=OL&E$A_\?_&O%?B5^U9_
MP4 _9.@DO_&&GWVH:3;?-+<MH=A?6:*.<O-:I\@_WF6OHL-P/4Q#Y*.,H.79
M5-?_ $D^;Q7'=+#KGK8/$1C_ #.GI_Z5H?L+17Y/_L[_ /!R5<B^M[+XI^!H
M#"Q"RZEX==D:/L2;>9B&]3B5?85^D/[._P"U#X$_:K\$C7_ ?B*QUZQ&U9TC
M)2XLW(R$FB;#QM_O#G&1D<UY6=<*YIE7O8RDU'^9:Q^];>CLSULDXMRK-O=P
M55.7\KTE]SW]5='?T45\$?\ !67_ (*:_%C_ ()Z_$W0(=#\+^#=8\(>)K)I
M+.\U"WNFG2YB8":%BDR+P&B8<<B3'\)-?.GTA][T5^=W_!+#_@M-K?[;'Q]N
MO ?CC1?#.A7EYI[W6C2Z6LT?VF:+YI(6$DKY)CW.,8P(FSG(K]$: "BBFRRK
M#&SNP5%!9F8X  [F@!U%?C[\</\ @Y$\;>'OB]XCL/!?A7P1J'A6QU":WTN[
MOHKIY[N!&*K*Q2=5^<#< %& P';-?H'_ ,$U_P!HOQ_^UC^S-9^/O'NCZ#H4
MNO74K:5:Z7%-&&LT(02R>;(YW-(LF,<;0I_BIV ]_HKS[]J[XMWWP%_9H\=^
M-=,M[2[U#PMHEUJ=M#=!C#+)%&SJKA2&VDCG!!]Z_+?X1?\ !Q7\5OB%\5_#
M6@7/@WX>Q6VM:K;6$KQ6]X'1)950E2;@C.&XR#]*+ ?L31112 **KZIJMMH>
MF7%[>W$%G9VD;33SSR".*%%&69F. J@ DD\#%?G!^V3_ ,'$_A+X7:O=:'\*
M-$C\;W]NQC?6+UV@TQ&&1^[1<23C(ZYC!Z@L* /TGHK^?OQW_P %W?VD_&5X
MTEMXRL?#T1;(@TS1K0(OL#+'(^/JQJU\.?\ @O;^T=X&O(WOO$VD^*8$.3!J
MNCVX5Q[M L3_ /CU.PKG[]45^??[$W_!P!X ^/VKV?A[XAV"_#SQ!=,(HKUI
M_-TBY<^LA :#/^WE1W>OT"BE6>)71E=' 964Y# ]"#2&.HHHH _)'_@Y]_Y#
M7P9_ZX:Q_P"A658'_!LI_P EK^)G_8$M_P#T?6__ ,'/O_(:^#/_ %PUC_T*
MRK _X-E/^2U_$S_L"6__ */JNA/4_8VO@'_@X\_Y,-T;_L<+/_TEO*^_J^ ?
M^#CS_DPW1O\ L<+/_P!);RI&]C\0M$UG4-)FE73[JZMI+V)K6402,AFC?AHS
MCJIZ$=#7Z^?L"?\ !OMX2MOAQIOB/XUQZCJOB#5(DN?^$?@N7M+?3$8 B.9X
MR)'EZ;@K*JG*_-C=7Y]_\$IOA1;_ !G_ ."@WPPT6\A%Q9IJPU&:-AE76UC>
MZVL.ZGR<$=\U_2'5,21\E^-_^"'_ .S7XRT)[.+P%)HDI4A+O3M6NUGB.,9'
MF2.A/^\K#VK\;O\ @I'^P9J?_!/_ ./[^&9KQM6T'4X!?Z)J+)L:YMRQ4K(!
MP)48%6 Z_*V & '](M?E[_P<V^%(+GX5?"[6S&OVJSU.]L@^.=DL43D?G"/U
MH3&R[_P;:?M(W?C#X1>,?AIJ-P\P\)7$>IZ4'.=EO<%Q-&OHJRJ'^L[5^FM?
MA]_P;=>()=._;AU^Q!_<ZCX1N@X]62YM&!_G^=?N#2>X+8*P]4\:QOHEU-HB
MP:_>PMY26UM<+@RGH)'&1&O<L1P < G /YJ_\'"_[;NL>!?[!^$7AC5+G33J
M=H=5\0R6LA1YH68I!;%ASM.R1W7N/+[9!^%O^"5WB?QQH_[=OPZM_!%W>17N
MHZQ!!?PQR$17-@&W72RKT9! )&.>FW(Y -?I&4>'=7%92\UJU5#1R46M&EW=
MU:]NSTU/S/./$>EA,W64T:3GJHN2>J;M\*L[VOU:UT/W1\+?LE:7J_CJ'QM\
M0WA\<^-8LFTDNXLZ;X?4G/E6%LV5CQQF9MTSD9+@84>O445^?8C%5:[3J.]M
M%V2[);)>A^BX?"TJ":I*U]6^K?=O=OS84A&X8-+17.=!\!_\%.O^"+?AG]H;
MPWJ7C'X9Z;:>'/']M&UQ)86J+#9:\1DE2@PL<YYPXP&)P_7>OY#_  &_:#\=
M?L<_%^'7_"VHWN@Z[I,QAN;>16"3A6P\$\1QN0D8*MR",C# $?TZ5^$__!?;
M]GZS^#G[;LFMZ; EO9>/=.CUF5$&%6[WO%/@>K&,2$]VE-?MOAKQ+5QDI9+F
M'[R+B^7FUT6\7?=6U5]K6[6_#/$WABE@HQSS+E[.2DN;ETU>TE;9WT=M[I[W
MO^N7["'[9>A_MR?L^Z=XRTE5L[X-]DU?3M^YM.O% +IGNA!#(W=6&<$$#D/^
M"LG[) _; _8P\1Z-9VWVCQ)H*_VYH>U<NUQ"K%HE]3+&9(P.FYE)Z5^;G_!O
M!\>KKP%^U_?^"7G/]E^.]+E7R2>/M5LK3QO^$8N%]]X]*_;BOS[C3(8Y1FL\
M-2^!VE'T?3Y--?(_1>",_EG&4PQ-7XU>,O5=?FFG\S^63X&_%W5OV?OC+X<\
M9:+)Y6J^&=1BOH<G"N48$HW^RPRK#N&(K^G;X.?%72OCC\*?#OC#1)/-TKQ+
MI\.H6Q/WE61 VUO1E)*D=B"*_!#_ (+.?LB?\,H?MI:U_9]MY'ACQIG7M)VK
MB.+S6/G0CL-DN_"CHC1^M?<'_!N)^UG_ ,)G\)O$/PCU2YW7_A.0ZMHZNW+6
M4SXF11Z1S,&_[>?:OE7L?6+L?II7R-_P6I_:R_X9=_8EUJ"QN/)\1^.MWA_3
M=K8>-)%/VB4=QMAW*&'1Y(Z^N:_ S_@NQ^UG_P -&_MH7N@Z=<^?X=^'"-HE
MJ%;*270;-W(/?S (_<0*:2&SYR_9(_9YU+]J[]H[PGX#TS>LWB&_2*>95S]E
MMQEYYC_N1*[8[[<=Z_IL\$>#=-^'/@S2?#^CVR66DZ)9Q6%E;I]V&&) B*/H
MJBOS$_X-O?V1O[)\,^)/C+JUM^^U,MH6@EUZ0H0US,O^\X2,'J/+E'>OU/H8
M(\4_X*0_\F"?&+_L4=1_])WK^=S]F/\ Y.2\ ?\ 8QZ?_P"E,=?T1_\ !2'_
M ),$^,7_ &*.H_\ I.]?SN?LQ_\ )R7@#_L8]/\ _2F.FA2/ZCJ**\/_ ."D
M'[0,W[,/[$WQ \7V<WV?5+73C9Z=(/O1W5PZV\3CW1I _P#P"I*/R\_X+@?\
M%0=0^-_Q'U+X2^"M1DM_ _ARX-MJUQ;R8_MV\0_,"1U@C884=&92_(V$>*_\
M$YO^"47C;]O[4I-3CF'AGP+83B&\URXA+^<XP6BMX\CS7 (SR%7(R<D*?"?V
M?OA!J'[1?QW\+^#-/;%]XIU6"P$I&X0B1P&D/LJDL?937]-OP;^$>A? 7X6Z
M%X.\-6:V.A^'K1+.UB'4JO5V/\3LQ+,W5F8D]:K8G<^6/A5_P06_9U^'FD11
M:EX<U;Q?>*FU[O5=5G1G/<A+=HD'MP<>IJA\9O\ @@%^S_\ $G1YDT'3-:\#
MZBP_=7.FZC+<(K=MT5PT@*^H4J?<5]N45-V4?S>_M^_\$W_'/_!/SQO!:Z\(
M]7\.:FQ&EZ_9QLMM=D<F-@<F*4#DH2>Y4L 37V=_P0=_X*>W]OXEL/@?X\U*
M2ZL;T>5X3OKA\O:R@9^PLQZQL ?+S]U@$&0RA?TM_:T_9KT3]K?]G[Q'X#UV
M*,P:S:LMM<,FYK"Z49AN$]&1\'CJ-RGAB*_F>O+;6?@K\498=\VE^(/"NIE"
M\;?O+2ZMY<9!_O*Z=?456Y.Q_5117#?LS?%Y?C[^SSX*\:JJ1MXGT6UU&6->
MD4LD2F1/^ ON7\**DH_,K_@Y]_Y#7P9_ZX:Q_P"A658'_!LI_P EK^)G_8$M
M_P#T?6__ ,'/O_(:^#/_ %PUC_T*RK _X-E/^2U_$S_L"6__ */JNA/4_8VO
M@'_@X\_Y,-T;_L<+/_TEO*^_J^ ?^#CS_DPW1O\ L<+/_P!);RI&]CX#_P""
M!L*R?\%)_"I(YCT_467V/V.4?R)K]^J_ ?\ X($_\I)/#'_8.U'_ -)):_?B
MFP05^:__  <P_P#)LWP__P"QE?\ ])I*_2BOS7_X.8O^39OA_P#]C*__ *32
M4@>Q\J_\&YW_ "?Y>_\ 8J7W_HZVK]TJ_"W_ (-SO^3_ "]_[%2^_P#1UM7[
MI4V"/YZO^"SGBFY\4_\ !2+XD-<.66RN;:SA4]$2.UA0 ?4@G\:]]_X-M?AS
M::[^TCXW\2SHLEQX?T);>VW#_5M<3 %Q[[8G7Z.:\W_X+X?!6Y^&7[>^J:[Y
M+C3O'%A;:I;R8^0ND:V\JY_O!H=Q'I(OK75_\&['QLL_ '[7>L^%;Z5(1XWT
M9X;0L<>9=0,)E3\8A/\ B .]?TIF$G6X*OA?^?,=NRY>;[DG<_F/+HJCQQ;%
M_P#/Z>_=N7+][:L?MK1117\U'].A1110 5^-/_!R?XTM-4_:/\"Z%$ZO=:3X
M?:YG _@\Z=PJGWQ%G'HP]:_9:OYO_P#@IKXR\4>.OV[/B9=^+()[74X-;GLX
MK>12ODVT)\NW"@_P^2L9!'#;MW\5?I_A1@?:YO+$7_AQ;_\  O=_)O\  _+/
M%S'^QR>.&M_$DEZ<OO??=+\3M/\ @B=HESK/_!2OX<M;@D6;WUQ,?[J"PN,Y
M_$@?C7]!E?DW_P &X_[*-[%KGBCXOZK:2PV8MSH6B-(A N'9E>YE7/4($1 P
MX)>0=5-?K)7-XHX^GB,Z]G3=_9Q47ZW<G]U[>IT^%. J8;(_:5%;VDG)>EE%
M??:_H?&/_!<O]D;_ (:7_8RO]:T^V\[Q+\.2^MV95<O+:A0+N(=\>6HDP.28
M%'>OQH_8(_:>N?V/OVL/"/C>-I?L6GW@@U2%,YGLI?W<ZX[G8Q*C^\JGM7],
M5Q;QW=N\4J)+%*I1T=<JZG@@CN*_FW_X*8_LG2?L:_MA>*/"D,+1:'/-_:>A
ML>CV,Q+1@'OL.Z(GNT35^=H_2'W/W8_;V_:YL/V6OV,O$OQ"LKRWFN9;!8=
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M .H/;WGPG\77+(Q&_3K7^T(V]P\!=<?C5GX??\$DOVBOB3J$<%I\+/$MB)&
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9** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
